Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis

Published:2016-10-27 Issue:2 Volume:102 Page:327-335
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Mascarenhas John O.,Talpaz Moshe,Gupta Vikas,Foltz Lynda M.,Savona Michael R.,Paquette Ronald,Turner A. Robert,Coughlin Paul,Winton Elliott,Burn Timothy C.,O’Neill Peter,Clark Jason,Hunter Deborah,Assad Albert,Hoffman Ronald,Verstovsek Srdan

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting Structure-activity Relationships: Unleashing the potential of selective Janus kinase 1 inhibitors;Bioorganic Chemistry;2024-08

2. Small-molecule-based targeted therapy in liver cancer;Molecular Therapy;2024-08

3. Insight into Janus kinases specificity: From molecular architecture to cancer therapeutics;MedComm – Oncology;2024-03

4. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease;Frontiers in Immunology;2024-02-06

5. Janus kinase inhibitors modify the fatty acid profile of extracellular vesicles and modulate the immune response;Heliyon;2024-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP